Actinium Pharmaceuticals has initiated the RADIANZ clinical trial to evaluate ATNM-400, a HER3-targeting radiotherapy, in patients with advanced solid tumors beyond prostate cancer. Building on promising early results in metastatic castration-resistant prostate cancer, this imaging study uses Zirconium-89 PET scans to assess tumor uptake and retention across cancers like lung, breast, colorectal, pancreatic, and ovarian. The trial aims to support the development of ATNM-400 as a pan-cancer treatment option for tumors expressing HER3, addressing treatment resistance and expanding therapeutic possibilities. Further clinical data will guide its potential use in multiple difficult-to-treat cancers.
Actinium Pharmaceuticals clinical trial news provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 19:11 WIB: out of 150 priced US health stocks, 67 rose and 75 fell. Notable movers include BFLY at USD 6.70 with a 1-day change of +2.92% and a typical hold time of 15 days, RLAY at USD 20.48 with +2.71% change and 32 days hold, and ABCL at USD 12.79 with +2.65% change and 42 days hold, with Pluang order activity heavily skewed to selling at 99%.
RUM Group Inc. reported a record quarterly revenue of $96.6 million for Q3 2026, a 290% increase year-over-year, surpassing expectations. Despite this, earnings per share were -$0.19, missing the estimate of -$0.11. The company achieved its first pro...
The 2026 Vertex CompOps™ Index reveals that just 16% of enterprises regularly discuss indirect tax at the board level, while 43% only address it when issues arise. Companies with board-level focus on indirect tax are four times less likely to have er...
Richtech Robotics announced its Intelligent Cleaning System at ISSA Show North America 2026, which integrates autonomous cleaning robots with CCTV cameras to enable proactive, targeted cleaning. This system uses real-time data to optimize cleaning ta...
Blue Gold Limited is reducing operating costs and restructuring its balance sheet to address financial obligations and comply with Nasdaq listing requirements. The company is cutting headcount, streamlining operations, and exploring creditor arrangem...
Longevity Health Holdings announced its Board is exploring strategic alternatives for its bio-aesthetic and therapeutic businesses to maximize stakeholder value. Options under consideration include mergers, sales, licensing, or partnerships. This mov...
